Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology Parks Corporation have announced a co-incubation plan aimed at promoting and incubating startups in the fields of infectious diseases and immunology.
Collaboration Objectives
The initiative seeks to accelerate the translation of cutting-edge science into innovative treatments, addressing unmet clinical needs and improving patient quality of life. This will be achieved by fostering research by startups and scientists, and investing in biotechnology companies focused on breakthrough therapies.
BIVF’s Focus Areas
BIVF is dedicated to advancing fields such as immuno-oncology, regenerative medicine, infectious diseases, and digital health. The fund supports startups and scientists in translating innovative research into practical solutions.
Hong Kong Science & Technology Parks Corporation’s Ecosystem
Hong Kong Science & Technology Parks Corporation highlights a vibrant innovation and technology ecosystem in Hong Kong, home to over 150 biotechnology companies, 3 unicorns, and more than 11,000 research talents. The organization focuses on cutting-edge fields like artificial intelligence, robotics, and biomedical technology, leveraging the Greater Bay Area’s core advantages to drive global development.-Fineline Info & Tech
